Search
Remibrutinib
go.drugbank.com/drugs/DB16852ApprovedInvestigationalThe FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. … [A274501, L54101] Remibrutinib has also been investigated in other inflammatory conditions,[A274511] such as autoimmune encephalomyelitis [A274501] and Sjögren's syndrome.[A274521]
Midostaurin
go.drugbank.com/drugs/DB06595ApprovedInvestigationalIt was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents. … It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors [A19108].
Synonyms: 4'-N-benzoylstaurosporineElexacaftor
go.drugbank.com/drugs/DB15444ApprovedInvestigational[A187361] It received FDA approval in October 2019 in combination with [tezacaftor] and [ivacaftor] as the combination product Trikafta<sup>TM</sup>. … [A187361] While dual corrector/potentiator combination therapy has proven useful in the treatment of a subset of CF patients,[A187358] their use is typically limited to patients who are homozygous for
Triprolidine
go.drugbank.com/drugs/DB00427ApprovedFirst generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness.
Mixtures: COUGH-EN LINCTUS, COUGH-EN LINCTUSSynonyms: (E)-2-[3-(1-pyrrolidinyl)-1-p-toluenepropenyl]pyridine, trans-1-(2-pyridyl)-3-pyrrolidino-1-p-tolylprop-1-eneAcebutolol
go.drugbank.com/drugs/DB01193ApprovedInvestigationalThe drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. … A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors.
Synonyms: N-(3-acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butanamidePralatrexate
go.drugbank.com/drugs/DB06813ApprovedInvestigational[A246703] Pralatrexate was approved by the FDA on September 24, 2009. … [A246693] Compared to methotrexate, pralatrexate has better accumulation in cancer cells.
Synonyms: N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid, (2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}amino)pentanedioic acidAprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigational[A263386,L50261] Aprocitentan was approved by the FDA in March 2024 for the treatment of hypertension in patients inadequately controlled with standard therapy. … [L50261] It was the first antihypertensive employing a novel mechanism to be approved in almost 40 years.[L50261]
Streptococcus pneumoniae type 3 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10321ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR, PNEUMOVAX 23 Injektionslösung in einer FertigspritzeAmifampridine
go.drugbank.com/drugs/DB11640ApprovedIt is currently used as the first-line symptomatic treatment for LEMS in adult patients and is ideally given as oral tablets in divided doses, three or four times a day. … It was first discovered in Scotland in the 1970s and its clinical effectiveness for neuromuscular disorders, including Lambert–Eaton myasthenic syndrome (LEMS), has been investigated in the 1980s [L3171
Danazol
go.drugbank.com/drugs/DB01406ApprovedInvestigationalDanazol has been used in the treatment of endometriosis and some benign breast disorders. … A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins.